Impact of the Australia—US Free Trade Agreement on Australian Medicines Regulation and Prices

@article{Faunce2010ImpactOT,
  title={Impact of the Australia—US Free Trade Agreement on Australian Medicines Regulation and Prices},
  author={T. Faunce and J. Bai and D. Nguyen},
  journal={Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector},
  year={2010},
  volume={7},
  pages={18 - 29}
}
  • T. Faunce, J. Bai, D. Nguyen
  • Published 2010
  • Economics
  • Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
The Australia—United States Free Trade Agreement (AUSFTA) came into force on 1 January 2005. Before and subsequently to the AUSFTA being concluded, controversy surrounded the debate over its impact on Australia's health policy, specifically on regulation of pharmaceutical patents and Australia's cost-effectiveness system relating to prescription medicine prices known as the Pharmaceutical Benefits Scheme (PBS). This article examines the expectations of both parties in the pharmaceutical sector… Expand
How the Australia-US free trade agreement compromised the pharmaceutical benefits scheme
Australia’s Pharmaceutical Benefits Scheme (PBS) has unquestioned democratic legitimacy as a piece of public health policy. The PBS was approved by a majority of people in a majority of States in theExpand
The Trans‐Pacific Partnership Agreement: challenges for Australian health and medicine policies
TLDR
Concern is that proposed TPPA multilateral investor–state dispute settlement procedures would allow US corporations to obtain damages against Australian governments through international arbitral proceedings if their investments are impeded by Australian public health and environment protection legislation. Expand
The High Price of “Free” Trade: U.S. Trade Agreements and Access to Medicines
TLDR
The pursuit of increasing levels of intellectual property protection in successive bilateral and regional trade agreements has been driven, at least in part, by a U.S. desire to achieve standards of protection it anticipated from the TRIPS Agreement, but failed to secure. Expand
Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union
TLDR
Key regulatory, governance and legal challenges associated with the UK's withdrawal from the European Union (EU) are mapped in terms of convergent and divergent pressures within the global pharmaceutical sector. Expand
AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v PFIZER: EVERGREENING AND MARKET POWER AS A BLOCKBUSTER DRUG GOES OFF PATENT.
  • T. Faunce
  • Engineering, Medicine
  • Journal of law and medicine
  • 2015
TLDR
This column explores the ACCC case in the context of Pfizer's broader strategies to preserve its income globally from this high sales volume drug in the period following its patent expiration. Expand
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
  • J. Karnon, L. Edney, M. Sorich
  • Economics, Medicine
  • Australian health review : a publication of the Australian Hospital Association
  • 2017
TLDR
The effects of the non-maintenance of equivalent prices when the comparators of pharmaceuticals listed on the Pharmaceutical Benefits Schedule on a cost-minimisation basis come off-patent and are subject to statutory price reductions are illustrated. Expand
The Trans-Pacific Partnership Agreement: Contradictions in Australia and in the Asia Pacific Region
The Trans Pacific Partnership Agreement (TPPA) is currently being negotiated between the US, Australia, New Zealand, Singapore, Brunei, Peru, Chile, Vietnam and Malaysia. The TPPA is intended toExpand
The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries
TLDR
The clause regarding compulsory licensing, extension of the patent term, data exclusivity, and patent linkage showed unclear definitions or the lack of adequate explanations, so a country who wants to join international agreements in the near future could amend domestic legislations to minimise the detrimental effect of international agreements on access to medicines. Expand
The Patenting of Biological Materials in the United States: A State of Policy Confusion
  • L. Palombi
  • Sociology, Political Science
  • Perspectives on Science
  • 2015
This paper discusses the genesis of human DNA patents and the legal confusion and ramifications that ensued. Beginning in the mid-1970s with policymakers and lawmakers in the United States,Expand
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
TLDR
A cohort-based state transition model was developed that predicted changes in bone mineral density, and calibrated fracture probabilities as a function of BMD, age and previous fracture to estimate differences in costs and QALYs gained over a 10-year time horizon. Expand
...
1
2
...

References

SHOWING 1-10 OF 22 REFERENCES
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
TLDR
To the extent that the AUSFTA medicines provisions may represent animportant precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will be of great interest to policy makers in other jurisdictions. Expand
Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
TLDR
Concerns are raised that the many concerned health and consumer organisations who have asked the Senate either not to pass the enabling legislation, or to delay its passage until a fairer deal in terms of public health can be obtained. Expand
Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?
  • T. Faunce
  • Business, Medicine
  • The Medical journal of Australia
  • 2007
TLDR
It is argued that the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007 includes several changes that will limit reference pricing under the Australian Pharmaceutical Benefits Scheme that were influenced by the Australia–United States Free Trade Agreement (AUSFTA). Expand
Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
TLDR
The extent of use of special pricing arrangements in Australia and how and where they are communicated to health professionals and the community is assessed. Expand
Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India
This article compares controversial health technology provisions in two important United States free trade agreements with developed nations: Australia and with South Korea. It examines theExpand
Australia-United States Free Trade Agreement
In this chapter, we explain and evaluate the AUSFTA primarily from an Australian perspective, given that most countries will be in a more or less analogous position to Australia when negotiating anExpand
Drug Price Reforms: The New F1–F2 Bifurcation
TLDR
The changes may allow PBS and patient savings through lower priced generics, but their impact on the price of patented medicines is uncertain in the authors' view. Expand
Pharmaceutical Innovation: Law & the Public's Health
  • K. Outterson
  • Medicine, Business
  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2009
TLDR
Patents and other related IP rights create significant gaps between marginal cost and retail price, generating many billions of dollars in profits (patent rents) for companies. Expand
High prices for generics in Australia - more competition might help.
  • L. Bulfone
  • Economics, Medicine
  • Australian health review : a publication of the Australian Hospital Association
  • 2009
TLDR
An analysis comparing dispensed Prices for the most commonly prescribed and the highest cost items in Australia with dispensed prices in the US finds the main cause for higher prices for a substantial number of generic products is the lack of price competition. Expand
Canada – Patent Protection of Pharmaceutical Products
This concise and detailed Handbook addresses some of the most complex issues raised by the implementation of the TRIPS Agreement globally. Among other themes, the Handbook explores the applicabilityExpand
...
1
2
3
...